Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03858972
Title Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC (CONTESSA 2)
Acronym CONTESSA 2
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Odonate Therapeutics, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ESP | CAN | AUS


No variant requirements are available.